The American Society of Clinical Oncologists (ASCO) hosted a global meeting in Chicago IL. Cicero was tasked with conducting a survey among European Oncologists to determine what impact, if any, the meeting had on current prescribing and treatment modalities. Cicero specifically targeted Medical Oncologists from the UK, Germany, Belgium, The Netherlands, and Hungary. The survey dealt with breast cancer, specifically triple negative breast cancer, and the drug treatment regime doctors use. The survey further divided the treatment regime used into 1st, 2nd, and 3rd line metastatic or recurrent cancers.